16.12.2021 - Waltham, MA, Dec. 16, 2021 (GLOBE NEWSWIRE) - LAVA Medtech Acquisition Corp. (the “Company”) (NASDAQ: LVACU) announced today that, commencing December 17, 2021, holders of the units sold in the Company’s initial public offering may elect to .
27.10.2021 - Waltham, MA , Oct. 26, 2021 (GLOBE NEWSWIRE) - LAVA Medtech Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq .
Financing will support development of first-in-class CNS-selective sodium channel modulatorsCHARLOTTESVILLE, VA / ACCESSWIRE / October 26, 2021 / GenEp, Inc., a biotechnology company developing therapies
Lumira Ventures Closes Two Funds Totalling US$255M finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Search jobs 10-Dec-2020 Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 Trial of CYR-064 for the Restoration of Chronic Smell and Flavor Loss
WASHINGTON, Dec. 10, 2020 /PRNewswire/ Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with the participation of additional investors. The funds will be used to complete a Phase 2 clinical trial of the company s lead product, CYR-064, in the U.S. and Europe. As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the company s board of directors.